AI Summary & Key Takeaways
AI InsightThere was no statistically significant correlations between the 68Ga-Pentixafor PET/CT and18F-FDG PET/CT positivity and disease activity, MM subtype, ISS phase, light chain disease, beta2microglobulin, albumin, creatinine,LDH, FLC and M protein levels in during scans. 68Ga-Pentixafor PET/CT cannot replace 18F-FDG PET/CT for diagnostic imaging ofpatients with multiple myeloma, 68Ga-PET/CT seem to be a valuable probe for patient stratification in the context of CXCR4-targetedradioligand therapy.
📌 3 Key Takeaways
Abstract
The aim of this study to demonstrate and compare the CXCR4 expression by means of 68Ga-Pentixafor PET/CT in patients withmultiple myeloma with standard clinical parameters and 18F-FDG PET/CT findings. Twenty-four (17 women, 7 men; mean age:58.9±12.7) multiple myeloma patients who had undergone 18F-FDG PET/CT imaging to evaluate the disease activity were included inthe study. 68Ga-Pentixafor PET/CT imaging was performed within an average period of 12 days after initial 18F-FDG PET/CT imaging.68Ga-Pentixafor PET and 18F-FDG PET/CT revealed focal pathological lesions in 13/24 (54%) and 16/24 (67%) patients, respectively.In 19/24 patients, both tracers showed concordant findings (CXCR4+ and FDG+ in 12 patients; CXCR4- and FDG- in 7patients).In the remaining 5 patients, findings were discordant. The number of focal lesions identified by means of 68Ga-Pentixafor and 18FFDG were 89 (44%) and 113 (56%), respectively. 68Ga-Pentixafor PET/CT showed more lesions in 2/12 (17%) patients, whereas18F-FDG PET/CT was proved to be superior in 7/12 (58%) patients. In the remaining 3/12 (25%) patients, both tracers detected anequal number of lesions. There was no significant difference in appendicular and axial skeletal and extramedullary distribution ratiosfor both PET/CT examinations (p> 0.05). There was no statistically significant correlations between the 68Ga-Pentixafor PET/CT and18F-FDG PET/CT positivity and disease activity, MM subtype, ISS phase, light chain disease, beta2microglobulin, albumin, creatinine,LDH, FLC and M protein levels in during scans. 68Ga-Pentixafor PET/CT cannot replace 18F-FDG PET/CT for diagnostic imaging ofpatients with multiple myeloma, 68Ga-PET/CT seem to be a valuable probe for patient stratification in the context of CXCR4-targetedradioligand therapy.
Özet
Bu çalışmanın amacı, multipl myelomalı hastalarda CXCR4 ekspresyonun Ga-68 PSMA Pentiksafor PET/BT ile gösterilmesi ve standart klinik parametreler ve 18F-FDG PET/BT bulguları ile karşılaştırılmasıdır. Çalışmaya multipl myelom tanısı ile hastalık aktivitesinin değerlendirilmesi amacıyla 18F-FDG PET/BT yapılan yirmi dört (17 kadın, 7 erkek; ort yaş: 58.9±12.7) hasta dahil edildi. Ga-68 Pentiksafor PET/BT, 18F-FDG PET/BT’yi takiben ortalama 12 günlük süre içinde uygulandı. Ga-68 Pentiksafor PET ve 18F-FDG PET/ BT, sırası ile 13/24 (%54) ve 16/24 (%67) hastada fokal patolojik lezyonları gösterdi. 19/24 hastada her iki yöntem uyumlu bulgular 12 hastada CXCR4 ve FDG+; 7 hastada CXCR4 ve FDG- gösterdi. Geri kalan 5 hastada ise bulgular uyumsuzdu. Ga-68 pentiksafor ve 18F-FDG PET ile ortaya konulan fokal lezyon sayısı sırası ile 89 (%44) and 113 (%56) idi. 2/12 (%17) hastada Ga-68 Pentiksafor PET/ BT daha fazla sayıda lezyon gösterirken, 7/12 (%58) hastada 18F-FDG PET/BT üstündü. Geri kalan 3/12 (%25) hastada ise her iki yöntem benzer sayıda lezyon gösterdi. Her iki yöntem ile saptanan apendiküler, aksiyel iskelet ve ekstramedüller lezyonların dağılımı arasındaki fark anlamlı değildi (p> 0.05). Ga-68 Pentiksafor ve 18F-FDG PET/BT pozitifliği ile hastalık aktivitesi, MM alt tipi, ISS fazı, hafif zincir hasalığı, beta2 mikroglobulin, albumin, kreatinin, LDH, FLC ve M protein düzeyleri arasında anlamlı ilişki saptanmadı. Ga-68 Pentiksafor PET/BT multipl myelomalı hastalarda tanısal görüntüleme yöntemi olarak 18FFDG PET/BT nin yerini alamaz, Ga-68 Pentiksafor PET/BT, CXCR-4 hedefli radyoligand tedavi planlanan hastalarda hasta seçimi amacıyla faydalı olabilir.